Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Prouroguanylin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Guanylate cyclase activator 2B, Guanylate cyclase C-activating peptide 2, Guanylate cyclase C-activating peptide II, GCAP-II, Uroguanylin, UGN, GUCA2B
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD191069200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

50 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.8–40 ng/ml

Limit of Detection

0.086 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 2.3%

Inter-assay (Run-to-Run)

n = 8; CV = 6.4%

Spiking Recovery

98,20%

Dilutation Linearity

109,00%

Crossreactivity

  • bovine Not tested
  • cat Not tested
  • dog Not tested
  • goat Not tested
  • hamster Not tested
  • horse Not tested
  • chicken Not tested
  • monkey Not tested
  • mouse Not tested
  • pig Not tested
  • rabbit Not tested
  • rat Not tested
  • sheep Not tested
  • human Yes
Summary

Features

  • It is intended for research use only.
  • The total assay time is less than 4 hours.
  • The kit measures prouroguanylin in serum, plasma (EDTA, citrate, heparin).
  • Assay format is 96 wells.
  • Quality Controls are human serum based.
  • No animal sera are used.
  • Standard is recombinant protein based.
  • Components of the kit are provided ready to use, concentrated or lyophilized.

Research topic

Oncology, Others, Renal disease

Summary

Prouroguanylin (about 9,7 kDa) is a biologically inactive form of uroguanylin circulating in a bloodstream. Uroguanylin is a small –molecular-weight peptide which has been shown to participate in the regulation of salt and water homeostasis in mammals via cGMP-mediated processes in the intestine, kidney and other epithelia.
Prouroguanylin levels are markedly increased in chronic renal failure. The severity of chronic renal disease correlates with the magnitude of increases in plasma prouroguanylin concentrations.

Uroguanylin/prouroguanylin levels also increased in the nephrotic syndrome. It may be concluded that uroguanylin/prouroguanylin is cleared from the circulation by the kidney and that reduced functioning renal mass and decreased glomerular filtration rates (GFR) lead to substantial increases in the concentrations of these peptides in serum and plasma. Circulating forms of uroguanylin and prouroguanylin are thought to be a major source of the urinary forms of biologically active uroguanylin. Both of these peptides can enter renal tubules by glomerular filtration. Prouroguanylin in the tubular lumen is than converted to active uroguanylin by tubular endoproteases because prouroguanylin is not detected in the urine.

Studies of pathogenesis of colorectal cancer demonstrate that prouroguanylin may serve as marker of colon tumors in the body. Recent experiments also refer to possibility of prouroguanylin to play a significant role at diagnostic and treatment of heart diseases.
Areas of investigation: Renal disease, Heart failure, Oncology

Product References (3)

References

  • Kaar G, Dieplinger B, Gabriel C, Haltmayer M, Mueller T. Proguanylin andprouroguanylin--assay evaluation and clinical analyte characterization. Clin ChimActa. 2011 Nov 20;412(23-24):2277-83. doi: 10.1016/j.cca.2011.08.016. Epub 2011Aug 24. PubMed PMID: 21888901. See more on PubMed
  • von Volkmann HL, Brønstad I, Gilja OH, R Tronstad R, Sangnes DA, Nortvedt R,Hausken T, Dimcevski G, Fiskerstrand T, Nylund K. Prolonged intestinal transitand diarrhea in patients with an activating GUCY2C mutation. PLoS One. 2017 Sep28;12(9):e0185496. doi: 10.1371/journal.pone.0185496. eCollection 2017. PubMedPMID: 28957388; PubMed Central PMCID: PMC5619782. See more on PubMed
  • Di Guglielmo MD, Tonb D, He Z, Adeyemi A, van Golen KL. Pilot Study Measuring the Novel Satiety Hormone, Pro-Uroguanylin, in Adolescents With and WithoutObesity. J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):489-495. doi:10.1097/MPG.0000000000001796. PubMed PMID: 29112082; PubMed Central PMCID:PMC5825243. See more on PubMed
Summary References (7)

References to Prouroguanylin

  • Fan X. Wang Y, London RM, Eber SL, Krause WJ, Freeman RH, Forte LR: Signaling Pathways for Guanylin and Uroguanyiln in the Digestive, Renal, Central Nervous, Reproductive, and Lymphoid Systems. Endocrinology 138, 4636–4648 (1997).
  • Forte LR: A novel role for uroguanylin in the regulation of sodium balance. Am Clin Invest 112, 1138–1141 (2003).
  • Forte LR, Freeman RH, Krause WJ, London RM: Guanylin peptides: cyclic GMP signalling mechanisms. Braz J med Biol Res 32(11), 1329–1336 (1999).
  • Forte LR, London RM, Freeman RH, Krause WJ: Guanylin peptides: renal actions mediated by cyclic GMP. Am J Physiol Renal Physiol 278, 180–191 (2000).
  • Hamra FK, Fan X, Krause WJ, Freeman RH, Chin DT, Smith ChE, Currie MG, Forte LR: Prouroguanylin and proguanylin: Purification from Colon, Structure, and Modulation of Bioactivity by Proteases. Endocrinology 137, 257–265 (1996).
  • Hidaka Y, Shimono Ch, Ohno M, Okumura N, Adermann K, Forshmann W-G, Shimonishi Y: Dual Function of the Propeptide of Prouroguanylin in the Folding of the Mature Peptide. J Biol Chem 257, 25155–25162 (2000).
  • Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR: Uroguanylin Treatment Suppresses Polyp Formation in the APCMin/+ Mouse and Induces Apoptosis in Human Colon Adenocarcinom Cells via Cyclic GMP. Cancer research 60, 5151–5157 (2000).
Related Products Docs